SMDAM
Sumitomo Mitsui DS Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.37M | Sell |
10,916
-252
| -2% | -$31.7K | 0.01% | 572 |
|
|
2025
Q1 | $1.24M | Sell |
11,168
-50
| -0.4% | -$5.53K | 0.01% | 586 |
|
|
2024
Q4 | $1.53M | Hold |
11,218
| – | – | 0.02% | 547 |
|
|
2024
Q3 | $1.29M | Sell |
11,218
-218
| -2% | -$25.1K | 0.01% | 584 |
|
|
2024
Q2 | $1.57M | Buy |
11,436
+90
| +0.8% | +$12.4K | 0.02% | 504 |
|
|
2024
Q1 | $1.56M | Buy |
11,346
+2,349
| +26% | +$324K | 0.02% | 506 |
|
|
2023
Q4 | $1.19M | Buy |
8,997
+628
| +8% | +$82.7K | 0.02% | 574 |
|
|
2023
Q3 | $942K | Sell |
8,369
-21
| -0.3% | -$2.36K | 0.01% | 565 |
|
|
2023
Q2 | $791K | Buy |
8,390
+214
| +3% | +$20.2K | 0.01% | 614 |
|
|
2023
Q1 | $828K | Hold |
8,176
| – | – | 0.01% | 588 |
|
|
2022
Q4 | $977K | Buy |
8,176
+46
| +0.6% | +$5.49K | 0.02% | 530 |
|
|
2022
Q3 | $863K | Buy |
8,130
+61
| +0.8% | +$6.48K | 0.02% | 527 |
|
|
2022
Q2 | $787K | Buy |
8,069
+2,150
| +36% | +$210K | 0.02% | 540 |
|
|
2022
Q1 | $555K | Sell |
5,919
-73
| -1% | -$6.85K | 0.01% | 638 |
|
|
2021
Q4 | $510K | Buy |
5,992
+1,472
| +33% | +$125K | 0.01% | 666 |
|
|
2021
Q3 | $433K | Sell |
4,520
-41
| -0.9% | -$3.93K | 0.01% | 676 |
|
|
2021
Q2 | $443K | Hold |
4,561
| – | – | 0.01% | 688 |
|
|
2021
Q1 | $443K | Hold |
4,561
| – | – | 0.01% | 658 |
|
|
2020
Q4 | $437K | Hold |
4,561
| – | – | 0.01% | 642 |
|
|
2020
Q3 | $438K | Buy |
4,561
+15
| +0.3% | +$1.44K | 0.01% | 596 |
|
|
2020
Q2 | $554K | Hold |
4,546
| – | – | 0.02% | 543 |
|
|
2020
Q1 | $393K | Sell |
4,546
-850
| -16% | -$73.5K | 0.02% | 549 |
|
|
2019
Q4 | $580K | Buy |
+5,396
| New | +$580K | 0.02% | 570 |
|
|
2019
Q2 | – | Sell |
-4,725
| Closed | -$416K | – | 765 |
|
|
2019
Q1 | $416K | Buy |
+4,725
| New | +$416K | 0.01% | 715 |
|